SCHEMBL2908006

SCHEMBL2908006

Nc1ncnc2[nH]nc(C#CCCO)c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 1/20 0.35
PIK3CD O00329 10/20 0.33
PIK3CA P42336 10/20 0.33
PIK3CB P42338 10/20 0.33
PIK3CG P48736 10/20 0.33
PRKDC P78527 10/20 0.33
MTOR P42345 2/20 0.33
SGK1 O00141 1/20 0.33
MEN1 O00255 1/20 0.33
DYRK3 O43781 1/20 0.33
EIF4E P06730 1/20 0.33
EIF2AK2 P19525 1/20 0.33
CSNK1D P48730 1/20 0.33
KMT2A Q03164 1/20 0.33
BRSK2 Q8IWQ3 1/20 0.33
AURKB Q96GD4 1/20 0.33
MKNK1 Q9BUB5 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
ABL1 P00519 3/20 0.32
SRC P12931 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL887826 0.88 AHCY (0.38) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL887848 0.83 PIK3CD (0.36) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL887659 0.79 TLR7 (0.30) TLR7
SCHEMBL2908004 0.78 PIK3CD (0.41) TLR7PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL887796 0.76 PIK3CD (0.41) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL12541357 0.74 DYRK1A (0.34) XDH
SCHEMBL22924982 0.74 ABL1 (0.32) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL19414367 0.73 RET (0.40) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL26789959 0.73 PIK3CD (0.39) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL1845744 0.73 PIK3CD (0.39) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7715989-B2 Systems and methods for predicting oligonucleotide melting temperature (TmS) ELITECH HOLDING B.V. (NL) 2010-05-11 US claimed
US-7553643-B2 Method for amplifying target nucleic acid sequences using a primer comprising an AP endonuclease-cleavable linker EPOCH BIOSCIENCES, INC. (US) 2009-06-30 US claimed
EP-1430147-B1 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS EPOCH BIOSCIENCES INC (US) 2013-05-22 EP disclosed
EP-1975256-B1 Modified oligonucleotides for mismatch discrimination EPOCH BIOSCIENCES INC (US) 2012-07-11 EP disclosed
EP-1261616-B1 MODIFIED OLIGONUCLEOTIDES FOR MISMATCH DISCRIMINATION EPOCH BIOSCIENCES INC (US) 2010-08-18 EP disclosed
US-7751982-B2 TM leveling methods ELITECH HOLDING B.V. (NL) 2010-07-06 US disclosed
US-7715989-B2 Systems and methods for predicting oligonucleotide melting temperature (TmS) ELITECH HOLDING B.V. (NL) 2010-05-11 US disclosed
EP-1995330-A1 Modified oligonucleotides for mismatch discrimination Epoch Biosciences, Inc. (US) 2008-11-26 EP disclosed
EP-1975256-A1 Modified oligonucleotides for mismatch discrimination Epoch Biosciences, Inc. (US) 2008-10-01 EP disclosed
EP-1944310-A2 Modified oligonucleotides for mismatch discrimination Epoch Biosciences, Inc. (US) 2008-07-16 EP disclosed
EP-1537488-A4 SYSTEMS AND METHODS FOR PREDICTING OLIGONUCLEOTIDE MELTING TEMPERATURES (TMS) EPOCH BIOSCIENCES INC (US) 2008-07-02 EP disclosed
EP-1537488-A2 SYSTEMS AND METHODS FOR PREDICTING OLIGONUCLEOTIDE MELTING TEMPERATURES (TMS) Epoch Biosciences, Inc. (US) 2005-06-08 EP disclosed
US-20050075491-A1 TM leveling methods EPOCH BIOSCIENCES, INC. (US) 2005-04-07 US disclosed
EP-1430147-A1 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS Epoch Biosciences, Inc. (US) 2004-06-23 EP disclosed
WO-2002099141-A9 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS EPOCH BIOSCIENCES INC (US) 2004-05-27 WO disclosed
US-6683173-B2 CONJUGATING OLIGONUCLEOTIDE WITH 3-SUBSTITUTED PYRAZOLO(3,4-D)PYRIMIDINES AND/OR 5-SUBSTITUTED PYRIMIDINE MINOR GROOVE BINDER EPOCH BIOSCIENCES, INC. 2004-01-27 US disclosed
US-20030235822-A1 Systems and methods for predicting oligonucleotide melting temperature (TmS) EPOCH BIOSCIENCES, INC. 2003-12-25 US disclosed
WO-2003107144-A2 SYSTEMS AND METHODS FOR PREDICTING OLIGONUCLEOTIDE MELTING TEMPERATURES (TMS) EPOCH BIOSCIENCES, INC. (US) 2003-12-24 WO disclosed
US-20030224359-A1 TMLEVELING METHODS EPOCH BIOSCIENCES, INC. 2003-12-04 US disclosed
WO-2002099141-A1 FLUORESCENT QUENCHING DETECTION REAGENTS AND METHODS EPOCH BIOSCIENCES, INC. (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075491-A1 TM leveling methods RNGTT, TYMS, NT5C3B TLR7 1864/4885PIK3CD 3875/4885PIK3CA 2315/4885
US-20030224359-A1 TMLEVELING METHODS PTBP3, RNGTT, DTYMK TLR7 1716/4885PIK3CD 4726/4885PIK3CA 3455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.